Perioperative Immunmodulation beim Nierenzellkarzinom - eine Standortbestimmung

M. Böhm; T. Klatte; E. P. Allhoff

doi:10.1055/s-2003-42008

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000007.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Aktuelle Urol 2003; 34(5): 319-327
DOI: 10.1055/s-2003-42008

Übersichtsarbeit

Perioperative Immunmodulation beim Nierenzellkarzinom - eine Standortbestimmung

Perioperative Immune Modulation in Renal Cell Carcinoma - Review of the Current SituationM. Böhm¹ , T. Klatte¹ , E. P. Allhoff¹

¹Urologische Klinik, Otto-von-Guericke Universität, Leipziger Str. 44, 39120 Magdeburg

Further Information

Publication History

Publication Date:
11 September 2003 (online)

Also available at

Abstract
Full Text
References

Buy Article Permissions and Reprints

Zusammenfassung

Die wesentlichen Therapieoptionen beim Nierenzellkarzinom sind Chirurgie und Immuntherapie. Die Chirurgie geht allerdings mit einer erheblichen perioperativen Immundysfunktion einher. Diese Immundysfunktion kann durch eine Vorbehandlung mit Interleukin-2 (IL-2) moduliert werden, was das tumorspezifische Überleben zu verbessern scheint. Die perioperative Immunmodulation könnte die therapeutische Lücke zwischen neoadjuvanter und adjuvanter Immuntherapie schließen. In diesem Artikel wird die verfügbare Literatur kritisch gesichtet und eigene Originaldaten an 63 Patienten präsentiert.

Abstract

Surgery and immunotherapy are the mainstay in the treatment of renal cell carcinoma. Surgery, however, is associated with considerable perioperative immunodysfunction. This immunodysfunction can be modulated by pretreatment with Interleukin-2 (IL-2), which appears to prolong tumour-specific survival. Perioperative immunomodulation could help close the therapeutic gap between neoadjuvant and adjuvant immunotherapy. This article reviews recent literature and presents original data of 63 patients.

Schlüsselwörter

Immunmodulation - perioperativ - Interleukin-2 - Nierentumor

Key words

Immunomodulation - perioperative - interleukin-2 - renal cancer

Literatur

1 Hermanek P, Schrott K M. Evaluation of the new tumor, nodes and metastasis classification of renal cell carcinoma. J Urol. 1990; 144 238-242

PubMed Search in Google Scholar
2 Carl P, Klein U, Gebauer A, Schmiedt E. The value of lymphography for the TNM classification of renal carcinoma. Eur Urol. 1977; 3 286-288

PubMed Search in Google Scholar
3 Giuliani L, Giberti C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol. 1990; 143 468-474

PubMed Search in Google Scholar
4 Sánchez de la Muela P, Zudaire J J, Robles J E, Rosell D, Aguera L, De Castro F, Isa W, Berián J M. Renal cell carcinoma: vena caval invasion and prognostic factors. Eur Urol. 1991; 19 284-290

PubMed Search in Google Scholar
5 Herrlinger A, Schrott K M, Schott G, Sigel A. What are the benefits of extended dissection of the regional lymph nodes in the therapy of renal cell carcinoma?. J Urol. 1991; 146 1224-1227

PubMed Search in Google Scholar
6 Eschwege P, Saussine C, Steichen G, Delepaul B, Drelon L, Jacqmin D. Radical nephrectomy for renal cell carcinoma 30 mm or less: long-term follow results. J Urol. 1996; 155 1196-1199

PubMed Search in Google Scholar
7 Takashi M, Takagi Y, Sakata T, Shimoji T, Miyake K. Clinicopathological characteristics of small renal cell carcinomas. Int Urol Nephrol. 1994; 26 621-629

PubMed Search in Google Scholar
8 Siminovitch J P, Montie J E, Straffon R A. Lymphadenectomy in renal adenocarcinoma. J Urol. 1982; 127 1090-1091

PubMed Search in Google Scholar
9 Hultén L, Rosencrantz M, Seeman T, Wahlqvist L, Åhrén C. Occurrence and localization of lymph node metastases in renal carcinoma. Scand J Urol Nephrol. 1969; 3 129-133

PubMed Search in Google Scholar
10 Robson C J, Churchill B M, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol. 1969; 101 297-301

PubMed Search in Google Scholar
11 Parry-Billings M, Baigrie R J, Lamont P M, Morris P J, Newsholme E A. Effects of major and minor surgery on plasma glutamine and cytokine levels. Arch Surg. 1992; 127 1237-1240

PubMed Search in Google Scholar
12 Hensler T, Hecker H, Heeg K, Heidecke C-D, Bartels H, Barthlen W, Wagner H, Siewert J R, Holzmann B. Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immun. 1997; 65 2283-2291

PubMed Search in Google Scholar
13 Allendorf J D, Bessler M, Whelan R L, Trokel M, Laird D A, Terry M B, Treat M R. Postoperative immune function varies inversely with the degree of surgical trauma in a murine model. Surg Endosc. 1997; 11 427-430

Crossref PubMed Search in Google Scholar
14 Kuntz C, Wunsch A, Bay F, Windeler J, Glaser F, Herfarth C. Prospective randomized study of stress and immune response after laparoscopic vs. conventional colonic resection. Surg Endosc. 1998; 12 963-967

Crossref PubMed Search in Google Scholar
15 Gitzelmann C A, Mendoza-Sagaon M, Talamini M A, Ahmad S A, Pegoli W J, Paidas C N. Cell-mediated immune response is better preserved by laparoscopy than laparotomy. Surgery. 2000; 127 65-71

Crossref PubMed Search in Google Scholar
16 Ogawa K, Hirai M, Katsube T, Murayama M, Hamaguchi K, Shimakawa T, Naritake Y, Hosokawa T, Kajiwara T. Suppression of cellular immunity by surgical stress. Surgery. 2000; 127 329-336

Crossref PubMed Search in Google Scholar
17 Leaver H A, Craig S R, Yap P L, Walker W S. Lymphocyte responses following open and minimally invasive thoracic surgery. Eur J Clin Invest. 2000; 30 230-238

Crossref PubMed Search in Google Scholar
18 Böhm M, Ittenson A, Philipp C, Röhl F-W, Ansorge S, Allhoff E P. Complex perioperative immunodysfunction in patients with renal cell carcinoma. J Urol. 2001; 166 831-836

PubMed Search in Google Scholar
19 Ashida S, Okuda H, Chikazawa M, Tanimura M, Sugita O, Yamamoto Y, Nakamura S, Moriyama M, Shuin T. Detection of circulating cancer cells with von Hippel-Lindau gene mutation in peripheral blood of patients with renal cell carcinoma. Clin Cancer Res. 2000; 6 3817-3822

PubMed Search in Google Scholar
20 McKiernan J M, Buttyan R, Bander N H, de-la-Taille A, Stifelman M D, Emanuel E R, Bagiella E, Rubin M A, Katz A E, Olsson C A, Sawczuk I S. The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9. Cancer. 1999; 86 492-497

Crossref PubMed Search in Google Scholar
21 Bilkenroth U, Taubert H, Riemann D, Rebmann U, Heynemann H, Meye A. Detection and enrichment of disseminated renal carcinoma cells from peripheral blood by immunogenetic cell separation. Int J Cancer. 2001; 92 577-582

Crossref PubMed Search in Google Scholar
22 Thèze J. The cytokine network and immune functions. New York: Oxford University Press 1999

Search in Google Scholar
23 Mocellin S, Wang E, Marincola F M. Cytokines and immune response in the tumor microenvironment. J Immunther. 2001; 24 392-407

PubMed Search in Google Scholar
24 Abbas A K, Lichtman A H, Pober J S. Cellular and molecular immunology. Philadelphia: Saunders 2000

Search in Google Scholar
25 Smith K A. IL-2. In: Oppenheim JJ, Feldman M (Hrsg.). Cytokine reference. London: Academic Press 2001: 113-126

Search in Google Scholar
26 Civallero M, Barni S, Nano R, Capelli E. Dendritic cells and interleukin-2: cytochemical and ultrastructural study. Histol Histopathol. 2000; 15 1077-1085

PubMed Search in Google Scholar
27 Schnurr M, Galambos P, Scholz C, Dauer M, Krug A, Hartmann G, Eigler A, Endres S. Deutsches Ärzteblatt . 2002; 99 A2408-A2416

PubMed Search in Google Scholar
28 Overwijk W W, Theoret M R, Restifo N P. The future of Interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J Sci AM. 2000; 6 Suppl 1 S76-S80

PubMed Search in Google Scholar
29 Hoffman D M, Figlin R A. Intratumoral interleukin-2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J Urol. 2000; 18 152-156

Crossref PubMed Search in Google Scholar
30 Larchian W A, Horiguchi Y, Nair S K, Fair W R, Heston W D, Gilboa E. Effectiveness of combined Interleukin-2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. Clin Cancer Res. 2000; 6 2913-2920

PubMed Search in Google Scholar
31 Dudley M E, Wunderlich J R, Robbins P F, Yang J C, Hwu P, Schwartzentruber D J, Topalian S L, Sherry R, Restifo N P, Hubicki A M, Robinson M R, Raffeld M, Duray P, Seipp C A, Rogers-Freezer L, Morton K E, Mavroukakis S A, White D E, Rosenberg S A. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes. Science. 2002; 298 850-854

Crossref PubMed Search in Google Scholar
32 Holden S A, Lan Y, Pardo A M, Wesolowski J S, Gillies S D. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. Clin Cancer Res. 2001; 7 2862-2869

PubMed Search in Google Scholar
33 Nichols P H, Ramsden C W, Ward U, Sedman P C, Primrose J N. Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer. Cancer Res. 1992; 52 5765-5769

PubMed Search in Google Scholar
34 Nichols P H, Ramsden C W, Ward U, Trejdosiewicz L K, Ambrose N S, Primrose J N. Perioperative modulation of cellular immunity in patients with colorectal cancer. Clin Exp Immunol. 1993; 94 4-10

PubMed Search in Google Scholar
35 Deehan D J, Heys S D, Simpson W, Broom J, McMillan D N, Eremin O. Modulation of the cytokine and acute-phase response to major surgery by recombinant interleukin-2. Br J Surg. 1995; 82 86-90

PubMed Search in Google Scholar
36 Böhm M, Ittenson A, Schierbaum K F, Röhl F-W, Ansorge S, Allhoff E P. Petreatment with interleukin-2 (IL-2) attenuates perioperative immunodysfunction in patients with renal cell carcinoma. Eur Urol. 2002; 41 458-468

Crossref PubMed Search in Google Scholar
37 Brivio F, Lissoni P, Alderi G, Barni S, Lavorato F, Fumagalli L. Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advances colorectal cancer patients. Oncology. 1996; 53 263-268

PubMed Search in Google Scholar
38 Brivio F, Brivio O, Lissoni P, Emanuelli G, Girlando M, Uggeri F. Presurgical neuroimmunotherapy with melatonin and interleukin-2 in cancer patients. In: Maestroni GJM, Conti A, Reiter RJ (Hrsg.). Therapeutic potential of melatonin. Front Horm Res. Basel: Karger 1997: 137-148

Search in Google Scholar
39 Masotti A, Morandini G, Ortolani R, Fumagalli L. Phase-II randomized study of preoperative IL-2 administration in operable NSCLC. Lung Cancer. 1998; 20 191-202

Crossref PubMed Search in Google Scholar
40 De Maeyer E, De Maeyer-Guignard J. Type I interferons. In: Bona CA, Revillard J-P (Hrsg.). Cytokines and cytokine receptors: physiology and pathological disorders. Amsterdam: Harwood Academic Publishers 2000: 316-333

Search in Google Scholar
41 Luft T, Pang K C, Thomas E, Hertzog P, Hart D N, Trapani J, Cebon J. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol. 1998; 161 1947-1953

PubMed Search in Google Scholar
42 Sedman P C, Ramsden C W, Brennan T G, Giles G R, Guillou P J. Effects of low dose perioperative interferon on the surgically induced suppression of antitumour immune responses. Br J Surg. 1988; 75 976-981

PubMed Search in Google Scholar
43 Fujioka T, Yoshida N, Hasegawa M, Ishikura K, Suzuki Y, Kubo T. Interleukin-2 expanded tumor-infiltrating lymphocytes and their response to preoperative α-interferon in patients with renal cell carcinoma. J Urol. 1994; 152 852-856

PubMed Search in Google Scholar
44 Houvenaeghel G, Bladou F, Blache J L, Olive D, Monges D, Jacquemier J, Chaudet H, Delpero J R, Guerinel G. Tolerance and feasibility of perioperative treatment with interferon-α2a in advanced cancers. Int Surg. 1997; 82 165-169

PubMed Search in Google Scholar
45 Sejima T, Miyagawa I. The evaluation of Fas/Fas ligand system in renal cell carcinoma - the effect of preoperative interferon-α therapy. Nippon Hinyokika Gakkai Zasshi. 1999; 90 826-832

PubMed Search in Google Scholar
46 Nielsen H J, Pedersen B K, Moesgaard F, Haahr P M, Kehlet H. Effect of ranitidine on postoperative suppression of natural killer cell activity and delayed hypersensitivity. Acta Chir Scand. 1989; 155 377-382

PubMed Search in Google Scholar
47 Katoh J, Tsuchiya K, Osawa H, Sato W, Matsumura G, Iida Y, Suzuki S, Hosaka S, Yoshii S, Tada Y. Cimetidine reduces impairment of cellular immunity after cardiac operations with cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1998; 116 312-318

PubMed Search in Google Scholar
48 O'Riordain M G, Fearon K C, Ross J A, Rogers P, Falconer J S, Bartolo D C, Garden O J, Carter D C. Glutamine-supplemented total parenteral nutrition enhances T-lymphocyte response in surgical patients undergoing colorectal resection. Ann Surg. 1994; 220 212-221

PubMed Search in Google Scholar
49 Kerrebijn J D, Simons P J, Balm A J, Tas M, Knegt P P, de Vries N, Tan I B, Drexhage H A. Thymostimulin enhancement of T-cell infiltration into head and neck squamous cell carcinoma. Head Neck. 1996; 18 335-342

Crossref PubMed Search in Google Scholar
50 Hamano K, Gohra H, Katoh T, Fujimura Y, Zempo N, Esato K. The preoperative administration of lentinan ameliorated the impairment of natural killer activity after cardiopulmonary bypass. Int J Immunopharmacol. 1999; 21 531-540

Crossref PubMed Search in Google Scholar
51 Hubel K, Mansmann G, Schafer H, Oberhauser F, Diehl V, Engert A. Increase of antiinflammatory cytokines in patients with esophageal cancer after perioperative treatment with G-CSF. Cytokine. 2000; 12 1797-1800

Crossref PubMed Search in Google Scholar
52 Bex A, Horenblas S, Meinhardt W, Verra N, de Gast G C. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur Urol. 2002; 42 570-576

Crossref PubMed Search in Google Scholar
53 Morris K T, Johnson N, Homer L, Walts D. A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg. 2000; 179 407-411

Crossref PubMed Search in Google Scholar
54 Oz M C, Whitworth G C, Liu E H. Complementary medicine in the surgical wards. JAMA. 1998; 279 710-711

Crossref PubMed Search in Google Scholar
55 Fair W R. Back to the future - the role of complementary medicine in urology. J Urol. 1999; 162 411-420

Crossref PubMed Search in Google Scholar
56 Bruss K, Salter C, Galán E. American Cancer Society's guide to complementary and alternative cancer methods. Atlanta: American Cancer Society 2000

Search in Google Scholar

PD Dr. med. Malte Böhm

Urologische Klinik · Otto-von-Guericke Universität

Leipziger Str. 44

39120 Magdeburg

Phone: 0391-67-15036

Fax: 0391-67-15094

Email: malte.boehm@medizin.uni-magdeburg.de